Price
No data yet.
Social Signal Score
Analyst Ratings
33 analystsRevenue
$487.78M-41.09%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark S. Ordan
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Employees
- 4,280
- Beta
- 0.65
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 2.40
Financials
Revenue
$487.78M-41.1%Net Income
$39.84M-58.7%EBITDA
$57.45M-68.3%Free Cash Flow
$123.94M-33.7%EPS (diluted)
$0.49-52.9%Shares Outstanding (diluted)
81.41M-12.6%Operating Expenses
$61.29MCash & Debt
$404.20MReturn of Capital
$42.74MRevenue by Segment (annual)
$1.91BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.91B | $165.39M | $1.94 |
| 2024 | $2.01B | $-99.07M | $-1.19 |
| 2023 | $1.99B | $-60.41M | $-0.73 |
| 2022 | $1.97B | $66.33M | $0.80 |
| 2021 | $1.91B | $130.96M | $1.52 |
| 2020 | $1.73B | $-796.49M | $-9.31 |
| 2019 | $1.78B | $-1.50B | $-17.78 |
| 2018 | $3.65B | $268.63M | $2.95 |
| 2017 | $3.46B | $320.37M | $3.42 |
| 2016 | $3.18B | $324.91M | $3.47 |
| 2015 | $2.78B | $336.32M | $3.59 |
| 2014 | $2.44B | $317.28M | $3.30 |
| 2013 | $2.15B | $280.52M | $2.77 |
| 2012 | $1.82B | $240.91M | $2.41 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from MD's reported EPS growth of -1.7% a year over 13 years.
- EPS in 5 years
- $1.78
- Implied price
- $19.58
- Return from $25.97
- -5.5% a year
To earn 15.0% a year on these assumptions you'd need to buy at $9.74 — -62.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 7 | 9 | 11 | 13 | 15 |
|---|---|---|---|---|---|
| -11.7% | -22.4% | -18.4% | -15.1% | -12.2% | -9.7% |
| -6.7% | -18.0% | -13.8% | -10.3% | -7.2% | -4.6% |
| -1.7% | -13.7% | -9.2% | -5.5% | -2.3% | 0.6% |
| 3.3% | -9.3% | -4.6% | -0.7% | 2.7% | 5.7% |
| 8.3% | -4.9% | 0.0% | 4.1% | 7.7% | 10.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120+0.00%Social Signal Score
Mentions (4)
- Newszacks.com·13d ago·Positive
Can Pediatrix Sustain Growth Despite Lower Patient Volumes? MD posts 4% year-over-year revenue growth in the second quarter of 2026 despite lower patient volumes, aided by stronger reimbursement and acquisitions.
View source ↗ - Newszacks.com·32d ago·Neutral
Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue? Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·46d ago·Positive
Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·54d ago·Positive
Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $0.65 per share
Typical surprise +26.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 4$0.63 vs $0.59beat
- Tue, May 5$0.44 vs $0.37beat
- Thu, Feb 19$0.50 vs $0.53miss
- Mon, Nov 3$0.67 vs $0.46beat
- Tue, Aug 5$0.53 vs $0.42beat
- Tue, May 6$0.33 vs $0.25beat
Estimates and results for MD via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MD officers and directors.
- Bought
- —
- Sold
- $4.0m
0 trades
17 trades
- Weis Shirley Asold
- Ordan Mark Ssold
- Rucker Michael A.sold
- Linynsky Laura Asold
- Ordan Mark Ssold
- Moore Mary Ann Esold
- Swift James Dsold
- Linynsky Laura Asold
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Donna Shalalahouse · FL27 · disclosed Apr 27, 2020 (195d later)Sell$50,001 - $100,000
- Greg Gianfortehouse · MT00 · disclosed Oct 29, 2018 (3d later)Sell$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.